Skip to main content
SpringerLink
Log in

Fentanyl sublingual tablet: a guide to its use in breakthrough pain in opioid-tolerant adults with cancer

  • Clinical Questions and Answers on Drug
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Fine PG. Breakthrough cancer pain: epidemiology, characteristics and management. CNS Drugs 2000; 13: 313–9

    Article  Google Scholar 

  2. Gordon DB, Dahl JL, Miaskowski C, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management. Arch Intern Med 2005; 165(14): 1574–80

    Article  PubMed  Google Scholar 

  3. Control of pain in adults with cancer: guideline 106. Edinburgh: Scottish Intercollegiate Guidelines Network, 2008 Nov

  4. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13(4): 331–8

    Article  PubMed  Google Scholar 

  5. Christrup LL, Lundorff L, Werner M. Novel formulations and routes of administration for opioids in the treatment of breakthrough pain. Therapy 2009; 6(5): 695–706

    Article  CAS  Google Scholar 

  6. Chwieduk CM, McKeage KM. Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. Drugs 2010; 70(17): 2281–8

    Article  PubMed  CAS  Google Scholar 

  7. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009 Oct 8; 25(12): 2877–85

    Article  PubMed  CAS  Google Scholar 

  8. Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 2011; 27(3): 519–30

    Article  PubMed  CAS  Google Scholar 

  9. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1(1): 15–30

    PubMed  CAS  Google Scholar 

  10. Maguire P, Tsai N, Kamal J, et al. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992 Mar 24; 213(2): 219–25

    Article  PubMed  CAS  Google Scholar 

  11. Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289–307

    Article  PubMed  CAS  Google Scholar 

  12. Abstral sublingual tablets: summary of product characteristics. Galashiels, UK; ProStrakan Ltd, 2010 Feb 17

  13. US Food and Drug Administration. FDA approves opioid analgesic to help cancer patients manage pain [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm239490.htm [Accessed 2011 Jan 26]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fentanyl sublingual tablet: a guide to its use in breakthrough pain in opioid-tolerant adults with cancer. Drugs Ther. Perspect 27, 6–9 (2011). https://doi.org/10.2165/11206550-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11206550-000000000-00000

Search

Navigation